Skip to content


Supprelin, Supprelin La, Vantas (histrelin) is a protein pharmaceutical. Histrelin was first approved as Supprelin on 1991-12-24. It is used to treat precocious puberty in the USA. It is known to target gonadotropin-releasing hormone receptor. Vantas's patent is valid until 2026-06-16 (FDA).
Trade Name Supprelin, Supprelin La, Vantas
Common Name Histrelin
Indication precocious puberty
Drug Class Prehormones or hormone-release stimulating peptides
Get full access now